» Articles » PMID: 25626682

Nef Promotes Evasion of Human Immunodeficiency Virus Type 1-infected Cells from the CTLA-4-mediated Inhibition of T-cell Activation

Abstract

CTLA-4 is a negative regulator of T-cell receptor-mediated CD4(+) T-cell activation and function. Upregulation of CTLA-4 during human immunodeficiency virus type 1 (HIV-1) infection on activated T cells, particularly on HIV-specific CD4(+) T cells, correlates with immune dysfunction and disease progression. As HIV-1 infects and replicates in activated CD4(+) T cells, we investigated mechanisms by which HIV-1 modulates CTLA-4 expression to establish productive viral infection in these cells. Here, we demonstrate that HIV-1 infection in activated CD4(+) T cells was followed by Nef-mediated downregulation of CTLA-4. This was associated with a decreased T-cell activation threshold and significant resistance to CTLA-4 triggering. In line with these in vitro results, quantification of pro-viral HIV DNA from treatment-naive HIV-infected subjects demonstrated a preferential infection of memory CD4(+)CTLA-4(+) T cells, thus identifying CTLA-4 as a biomarker for HIV-infected cells in vivo. As transcriptionally active HIV-1 and Nef expression in vivo were previously shown to take place mainly in the CD3(+)CD4(-)CD8(-) [double-negative (DN)] cells, we further quantified HIV DNA in the CTLA-4(+) and CTLA-4(-) subpopulations of these cells. Our results showed that DN T cells lacking CTLA-4 expression were enriched in HIV DNA compared with DN CTLA-4(+) cells. Together, these results suggested that HIV-1 preferential infection of CD4(+)CTLA-4(+) T cells in vivo was followed by Nef-mediated concomitant downregulation of both CD4 and CTLA-4 upon transition to productive infection. This also highlights the propensity of HIV-1 to evade restriction of the key negative immune regulator CTLA-4 on cell activation and viral replication, and therefore contributes to the overall HIV-1 pathogenesis.

Citing Articles

Double-Negative T-Cells during Acute Human Immunodeficiency Virus and Simian Immunodeficiency Virus Infections and Following Early Antiretroviral Therapy Initiation.

Yero A, Shi T, Clain J, Zghidi-Abouzid O, Racine G, Costiniuk C Viruses. 2024; 16(10).

PMID: 39459942 PMC: 11512404. DOI: 10.3390/v16101609.


Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV.

Benito J, Restrepo C, Garcia-Foncillas J, Rallon N Front Immunol. 2023; 14:1270881.

PMID: 38130714 PMC: 10733458. DOI: 10.3389/fimmu.2023.1270881.


Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4.

Fisher K, Schlub T, Boyer Z, Rasmussen T, Rhodes A, Hoh R Front Immunol. 2023; 14:1064346.

PMID: 36776833 PMC: 9909745. DOI: 10.3389/fimmu.2023.1064346.


Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion.

Chan Y, Cheong H, Tang T, Rajasuriar R, Cheng K, Looi C Biomedicines. 2022; 10(11).

PMID: 36359329 PMC: 9687279. DOI: 10.3390/biomedicines10112809.


Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.

Sun Y, Xue J Viruses. 2022; 14(3).

PMID: 35336991 PMC: 8955100. DOI: 10.3390/v14030581.


References
1.
Kaiser P, Joos B, Niederost B, Weber R, Gunthard H, Fischer M . Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol. 2007; 81(18):9693-706. PMC: 2045436. DOI: 10.1128/JVI.00492-07. View

2.
Mellors J, Munoz A, Giorgi J, Margolick J, Tassoni C, Gupta P . Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126(12):946-54. DOI: 10.7326/0003-4819-126-12-199706150-00003. View

3.
Trautmann L, Said E, Halwani R, Janbazian L, Chomont N, El-Far M . Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections. Curr Opin HIV AIDS. 2009; 2(3):219-27. DOI: 10.1097/COH.0b013e3280ebb5c9. View

4.
Williams M, Roeth J, Kasper M, Fleis R, Przybycin C, Collins K . Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. J Virol. 2002; 76(23):12173-84. PMC: 136906. DOI: 10.1128/jvi.76.23.12173-12184.2002. View

5.
Olivieri K, Mukerji J, Gabuzda D . Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2. Retrovirology. 2011; 8:64. PMC: 3169461. DOI: 10.1186/1742-4690-8-64. View